Moderna reports second quarter 2022 financial results and provides business updates

Second quarter 2022 revenues of $4.7 billion; gaap net income of $2.2 billion and gaap diluted eps of $5.24 company reiterates advance purchase agreements for expected delivery in 2022 of approximately $21 billion company announces new $3 billion share repurchase plan company has four infectious disease vaccines in phase 3 and expects data from proof-of-concept studies in rare diseases and immuno-oncology later this year cambridge, ma / accesswire / august 3, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today reported financial results and provided business updates for the second quarter of fiscal year 2022. "today's earnings represent a strong second quarter performance, with $10.8 billion in revenue for the first half of the year.
MRNA Ratings Summary
MRNA Quant Ranking